Eze Chukwuka, Roengvoraphoj Olarn, Niyazi Maximilian, Hildebrandt Guido, Fietkau Rainer, Belka Claus, Manapov Farkhad
Department of Radiation Oncology, LMU Munich, Munich, Germany.
Department of Radiation Oncology, University of Rostock, Rostock, Germany.
Clin Lung Cancer. 2017 Jul;18(4):e243-e249. doi: 10.1016/j.cllc.2016.11.005. Epub 2016 Nov 21.
Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival.
The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and complete response only when cranial magnetic resonance imaging before and after primary treatment revealed no BMs. Correlation between PCI and overall survival (OS), BM-free survival (BMFS), and time to progression (TTP) was analyzed to describe survival within subgroups.
Concurrent and sequential chemoradiotherapy was applied in 71 patients (39%) and 113 patients (61%), respectively. Seventy-one patients (39%) with partial and complete response were treated with PCI. Metachronous BMs were detected in 16 (23%) of 71 patients in the PCI group compared to 42 (37%) of 113 patients in the non-PCI group. Median BMFS in the PCI group was not reached; it was 23.6 months in the non-PCI group. Median OS and TTP were 26 months (range, 19.4-32.6 months) in the PCI group versus 14 months (range, 11.4-16.6 months) in patients without PCI whose disease responded to therapy versus 9 months in patients with disease that did not respond to therapy (P < .0001), and 27 versus 14.5 months (range, 9.0-19.9 months) versus 8.8 months (range, 7.7-9.9 months) (P < .0001) in the PCI group versus those with response without PCI versus those with nonresponse. The effect of PCI was independent of gender. On multivariate analysis, PCI was a variable correlating with OS (hazard ratio = 1.899; 95% confidence interval, 1.370-2.632; P < .0001) and TTP (hazard ratio = 2.164; 95% confidence interval, 1.371-3.415; P = .001) after adjustment for other prognostic factors.
In real-life patients comprehensively staged with cranial magnetic resonance imaging, treatment response and PCI strongly correlated with prolonged OS, TTP, and BMFS.
预防性颅脑照射(PCI)已被证明可降低脑转移瘤(BMs)的发生率,并适度提高生存率。
对184例接受放化疗的患者评估PCI的影响。仅当原发治疗前后的头颅磁共振成像未显示BMs时,才对部分缓解和完全缓解的患者应用PCI。分析PCI与总生存期(OS)、无BM生存期(BMFS)和疾病进展时间(TTP)之间的相关性,以描述亚组内的生存情况。
同步放化疗和序贯放化疗分别应用于71例(39%)和113例(61%)患者。71例部分缓解和完全缓解的患者接受了PCI治疗。PCI组71例患者中有16例(23%)检测到异时性BMs,而非PCI组113例患者中有42例(37%)。PCI组的中位BMFS未达到;非PCI组为23.6个月。PCI组的中位OS和TTP分别为26个月(范围19.4 - 32.6个月),而疾病对治疗有反应的非PCI患者为14个月(范围11.4 - 16.6个月),疾病对治疗无反应的患者为9个月(P <.0001),PCI组与对治疗有反应的非PCI患者及无反应患者相比分别为27个月对14.5个月(范围9.0 - 19.9个月)对8.8个月(范围7.7 - 9.9个月)(P <.0001)。PCI的效果与性别无关。多因素分析显示,在调整其他预后因素后,PCI是与OS(风险比 = 1.899;95%置信区间,1.370 - 2.632;P <.0001)和TTP(风险比 = 2.164;95%置信区间,1.371 - 3.415;P =.001)相关的变量。
在通过头颅磁共振成像进行全面分期的实际患者中,治疗反应和PCI与延长的OS、TTP和BMFS密切相关。